HK1126812A1 - 病症的治療 - Google Patents

病症的治療

Info

Publication number
HK1126812A1
HK1126812A1 HK09105618.2A HK09105618A HK1126812A1 HK 1126812 A1 HK1126812 A1 HK 1126812A1 HK 09105618 A HK09105618 A HK 09105618A HK 1126812 A1 HK1126812 A1 HK 1126812A1
Authority
HK
Hong Kong
Prior art keywords
cns
treatment
conditions
cns conditions
conditions cns
Prior art date
Application number
HK09105618.2A
Other languages
English (en)
Inventor
Antn Ana Isabel Jimnez
Yague Angela Sesto
Gomez M Concepcin Jimnez
Gullon Eduardo Gomez-Acebo
Original Assignee
Sylentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sa filed Critical Sylentis Sa
Publication of HK1126812A1 publication Critical patent/HK1126812A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK09105618.2A 2006-03-17 2009-06-23 病症的治療 HK1126812A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605337.5A GB0605337D0 (en) 2006-03-17 2006-03-17 Treatment of CNS conditions
PCT/GB2007/050128 WO2007107789A2 (en) 2006-03-17 2007-03-16 Treatment of cns conditions

Publications (1)

Publication Number Publication Date
HK1126812A1 true HK1126812A1 (zh) 2009-09-11

Family

ID=36292900

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105618.2A HK1126812A1 (zh) 2006-03-17 2009-06-23 病症的治療

Country Status (14)

Country Link
US (1) US8871729B2 (zh)
EP (1) EP2004823B1 (zh)
JP (2) JP5781722B2 (zh)
KR (2) KR101605144B1 (zh)
CN (1) CN101448944B (zh)
AU (1) AU2007228570B2 (zh)
CA (1) CA2645120C (zh)
ES (1) ES2582649T3 (zh)
GB (1) GB0605337D0 (zh)
HK (1) HK1126812A1 (zh)
IL (1) IL194114A (zh)
MX (1) MX2008011731A (zh)
RU (1) RU2426544C2 (zh)
WO (1) WO2007107789A2 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578692B1 (en) * 2007-04-05 2016-06-08 The J. David Gladstone Institutes Agents that reduce neuronal overexcitation
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
CA2773886C (en) * 2009-09-11 2018-01-09 Isis Pharmaceuticals, Inc. Modulation of huntingtin expression
WO2011066475A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
US20110135613A1 (en) 2009-12-03 2011-06-09 The J. David Gladstone Institutes Methods for treating apolipoprotein e4-associated disorders
US8778904B2 (en) 2009-12-09 2014-07-15 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the CNS
CA2789404C (en) * 2010-02-26 2020-03-24 Memorial Sloan-Kettering Cancer Center Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
KR20130103662A (ko) 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
US9949923B2 (en) * 2011-03-15 2018-04-24 Optinose As Nasal delivery
EP2822600A4 (en) * 2012-03-09 2016-04-06 Univ Northeastern METHOD OF DISTRIBUTING NUCLEIC ACID ANOPARTICLES TO THE CENTRAL NERVOUS SYSTEM FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
AU2013202595B2 (en) * 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
US20140302510A1 (en) * 2012-04-06 2014-10-09 Centre National De La Recherche Scientifique Method of diagnosis, prognostic or treatment of neurodegenerative diseases
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
JP6386461B2 (ja) 2012-10-26 2018-09-05 エヌライフ、セラピューティックス、ソシエダッド、リミターダＮｌｉｆｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｓ．Ｌ． 特定のニューロン種へのオリゴヌクレオチド分子の選択的送達によるパーキンソン病の治療のための組成物および方法
US9644207B2 (en) * 2013-03-14 2017-05-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
JP2016523980A (ja) * 2013-07-11 2016-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク タウ発現を抑制するマイクロｒｎａ
TWI657819B (zh) 2013-07-19 2019-05-01 美商Ionis製藥公司 用於調節τ蛋白表現之組合物
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
EP3080611B1 (en) * 2013-12-13 2018-11-14 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
US10513701B2 (en) 2015-03-25 2019-12-24 Università Degli Studi Di Trento RNA interference mediated therapy for neurodegenerative diseases
JOP20200228A1 (ar) * 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
CN112501208A (zh) * 2017-10-03 2021-03-16 普利维尔治疗公司 用于溶酶体障碍的基因疗法
CN112481269A (zh) 2017-10-03 2021-03-12 普利维尔治疗公司 用于溶酶体障碍的基因疗法
AU2019233612A1 (en) * 2018-03-13 2020-09-10 Janssen Pharmaceutica Nv Modified oligonucleotides for use in treatment of tauopathies
CA3171246A1 (en) * 2020-03-18 2021-09-23 University Of Massachusetts Oligonucleotides for mapt modulation
CN113817728A (zh) * 2020-06-19 2021-12-21 四川大学华西医院 一种有效干扰Tau蛋白表达的重组慢病毒及其应用
AR129311A1 (es) * 2022-05-12 2024-08-14 Dicerna Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión de mapt
WO2024145474A2 (en) * 2022-12-29 2024-07-04 Voyager Therapeutics, Inc. Compositions and methods for regulating mapt

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
US6410046B1 (en) * 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
WO2002086105A1 (en) * 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
US20050159376A1 (en) 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
IL143379A (en) 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20050222061A1 (en) 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
AU2003282877B9 (en) 2002-09-25 2011-05-12 University Of Massachusetts In Vivo gene silencing by chemically modified and stable siRNA
AU2003279010A1 (en) 2002-09-28 2004-04-19 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
AU2003290586B2 (en) * 2002-11-04 2009-07-02 University Of Massachusetts Allele-specific RNA interference
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
EP2508608A1 (en) 2003-06-09 2012-10-10 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMERIC COMPOUNDS FOR GENE MODULATION
CA2528963A1 (en) 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
US20070185042A1 (en) 2003-08-08 2007-08-09 The Brigham And Women's Hospital, Inc. President And Fellows Of Harvard College Sirna based methods for treating alzheimer's disease
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1735443A2 (en) 2004-04-14 2006-12-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050265927A1 (en) 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
WO2006041922A2 (en) 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system

Also Published As

Publication number Publication date
IL194114A0 (en) 2011-08-01
RU2426544C2 (ru) 2011-08-20
AU2007228570A8 (en) 2008-10-23
MX2008011731A (es) 2009-03-05
JP5923466B2 (ja) 2016-05-24
GB0605337D0 (en) 2006-04-26
EP2004823B1 (en) 2016-05-25
JP5781722B2 (ja) 2015-09-24
AU2007228570A1 (en) 2007-09-27
WO2007107789A2 (en) 2007-09-27
AU2007228570B2 (en) 2013-09-19
KR101605144B1 (ko) 2016-03-21
CN101448944A (zh) 2009-06-03
RU2008141162A (ru) 2010-04-27
JP2013234197A (ja) 2013-11-21
CA2645120C (en) 2015-02-24
KR20140076634A (ko) 2014-06-20
KR20080111063A (ko) 2008-12-22
CN101448944B (zh) 2014-02-12
JP2009530257A (ja) 2009-08-27
KR101669944B1 (ko) 2016-10-28
IL194114A (en) 2012-06-28
US20090176728A1 (en) 2009-07-09
ES2582649T3 (es) 2016-09-14
WO2007107789A3 (en) 2008-05-08
EP2004823A2 (en) 2008-12-24
CA2645120A1 (en) 2007-09-27
US8871729B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
IL194114A0 (en) Treatment of cns conditions
ZA200710598B (en) Treatment of inflammatory conditions
GB2454797B (en) Treatment of wastewater
EP2032131A4 (en) Methods of Treatment
EP2046349A4 (en) TREATMENT OF EXCESSIVE NEOVASCULARIZATION
SI2029155T1 (sl) Izboljšano zdravljenje multiplega mieloma
GB0608190D0 (en) Method of purification
GB0610746D0 (en) Method of treatment
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
GB0619500D0 (en) Treatment of fibrosis
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
GB0607952D0 (en) Novel treatment
GB0515035D0 (en) Treatment of atherosclerotic conditions
PL2198431T3 (pl) Oczyszczanie metali
GB0723100D0 (en) Treatment of HFnEF
EP2164494A4 (en) Methods of Treatment
IL194798A0 (en) Treatment of melanoma
GB0618060D0 (en) Treatment of polyamides
GB0611417D0 (en) Treatment of cndaria intoxication
GB0618403D0 (en) Treatment of amyotrophic lateral sclerosis
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
ZA200902765B (en) Treatment of pulp
GB0602857D0 (en) The treatment of sialorrhoea
GB0625602D0 (en) Treatment of sialorrhoea
GB2443891B (en) Process for the purification of meloxicam